Monitor for follow-up transactions, particularly from other C-suite executives, as isolated CFO selling paired with a small board buy is not strongly directional at this volume. No immediate catalyst is evident.
DYN drugs
DYN drug pipeline →- ▲ z-rostudirsen 8/10 Filed (BLA under FDA Priority Review); Phase 3 confirmatory trial (FORZETTO) ongoing · PDUFA date Jan 21, 2027
- ◆ z-basivarsen 7/10 Phase 3 (HARMONIA confirmatory trial, initiated March 2026); Phase 1/2 registrational cohort (ACHIEVE) fully enrolled · BLA filing Q3 2027
- ● DYNE-302 2/10
- All DYN drugs, catalysts & trials →
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 30 $17.09entry
- T+1 · 8mo ago +6.09%α +3.19% · $18.13
- T+5 · 7mo ago +6.26%α +1.96% · $18.16
- T+20 · 7mo ago +6.26%α −6.34% · $18.16
- T+60 · 5mo ago +20.60%α +4.11% · $20.61
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
A mixed insider trading cluster at Dyne Therapeutics shows CFO Erick Lucera selling $107K in shares while Director Brian Posner bought $34K, all within a 7-day window. The net selling by a C-suite executive outweighs the board-level purchase, but total volume remains below 0.1% of market cap.
Key Financial Metrics
Key Facts
- CFO Erick Lucera sold 5,727 shares for $106,751 in open-market transactions on April 1, 2026.
- Director Brian Posner purchased 2,000 shares for $34,160 on March 30, 2026.
- Total cluster value is $140,911, representing just 0.0045% of Dyne Therapeutics' $3.1B market cap.
- Net direction is mixed, with $107K in sales and $34K in purchases by corporate insiders.
Financial Impact
$141K total insider activity, net $73K in selling over 7 days
Risk Factors
- CFO selling could signal caution ahead of a key clinical readout or financing need.
- Low trade volume limits interpretive power; activity may be routine portfolio management.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-DYN-1775247052856 |
Track record
54 reports on DYN
12 of 16 bullish or bearish reports moved the stock their way by T+20. Best: +46.36% at T+60 after the May 20, 2026 report. 15 of 16 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $16.77 Now $16.70 −0.39% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $17.36 Now $16.70 −3.80% settles Dec 4
- Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $17.04 Now $16.70 −2.00% settles Nov 27
- Oct 22, 202625d ago Press Release Neutral 2/10 Entry $15.62 Now $16.70 +6.91% settles Nov 20
- Oct 12, 20265w ago Institutional Cluster Mixed 4/10 Entry $15.96 to $18.62 Now $16.70 +4.64% ▲ +16.67% +19.93% vs SPY
- Sep 29, 20266w ago Press Release Bullish 7/10 Entry $16.11 to $16.94 Now $16.70 +3.66% ▲ +5.15% +4.23% vs SPY
- Sep 8, 20269w ago Insider Cluster Neutral 3/10 Entry $19.19 to $15.97 Now $16.70 −12.98% ▼ −16.78% −18.72% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers